To restore blood flow is the principal way to treat ischemic stroke clinically, fibrinolytic therapy by recombinant tissue plasminogen activator (rt-PA), the only thrombolytic drug approved by the US Food and Drug Administration in 1996, is still the most efficient treatment for ischemic stroke [6], but only few percentage of patients are eligible for rt-PA therapy, because of its secondary reperfusion injury [7, 8]. Here, PLAT is linked to ischemic stroke.